Namilumab
Namilumab (pronounced na-mi-lu-mab) is a human monoclonal antibody designed for the treatment of various autoimmune diseases. It is a therapeutic agent that targets granulocyte-macrophage colony-stimulating factor (GM-CSF), a protein that plays a crucial role in inflammation.
Etymology
The name "Namilumab" follows the INN naming convention for monoclonal antibodies, with the suffix "-mab" indicating it is a monoclonal antibody. The prefix "Nami-" does not have a specific meaning in the INN system.
Mechanism of Action
Namilumab works by binding to GM-CSF, a protein that stimulates the production of white blood cells and promotes their activation. By blocking GM-CSF, Namilumab can reduce inflammation and potentially slow the progression of autoimmune diseases.
Clinical Trials
Namilumab has been tested in clinical trials for several conditions, including rheumatoid arthritis and psoriatic arthritis. The results of these trials have shown promise, but further research is needed to fully understand the potential benefits and risks of this treatment.
Related Terms
See Also
External links
- Medical encyclopedia article on Namilumab
- Wikipedia's article - Namilumab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski